Warm eyelid therapy offers hope for young dry eye sufferers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years but \<30 years of age 2. Non-invasive Keratograph break-up time (NIKBUT) \<10 seconds in at least one eye 3. Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid 4. OSDI ≥23 Exclusion Criteria: 1. Contact lens wear within two weeks of study enrollment or planned during study period 2. Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20/40) in either eye 3. Previous or current diagnosis of any autoimmune condition 4. Use of any of the following medications within 60 days of enrollment: 1. Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions) 2. Xiidra® 3. Miebo® 4. Tyrvaya® 5. Tryptyr® 5. Use of topical ocular steroids within 30 days of enrollment 6. Use of any other topical ophthalmic drop, excluding artificial tears, within 7 days 7. Use of oral tetracyclines or oral azithromycin within 30 days 8. Present or past use of oral isotretinoin 9. Any of the following procedural treatments for MGD in the past: 1. LipiFlow® 2. TearCare® 3. iLux® 4. Intense pulsed light (IPL) 10. Previous intraocular surgery within 6 months of enrollment 11. Previous refractive surgery within 2 years of enrollment 12. Current or planned pregnancy during the study period 13. Current or planned lactation during the study period 14. Females of childbearing potential who are not using effective contraception 15. Dose modification of oral antihistamines or antidepressants within 30 days of enrollment 16. Current enrollment or enrollment within 60 days in any other study of an investigational drug or device 17. Clinical opinion of the study doctor based on clinical examination and/or participant compliance with protocol requirements